Anika Therapeutics (ANIK) 10-Q2013 Q1 Quarterly report

Filed: 6 May 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: Affordable, aforementioned, American, announced, Arabia, arbitration, ATMP, attain, Austria, begun, behalf, biodegradable, bleeding, bracket, broaden, built, Canada, cell, complex, compliant, consent, conveyance, counterclaim, country, cumulative, Derecognition, disposal, diversity, doubled, economic, economy, Education, Egypt, EMA, engineering, entirety, entitled, established, estate, excise, expansion, extended, external, failing, February, focused, focusing, formulation, gas, hemostatic, human, Hyalofast, HYALOMATRIXPA, implementation, inability, innovative, Inspite, Latin, launch, London, marrow, MDET, mesenchymal, Mexico, mineral, Misonix, MONOVISCTM, mutual, nonprofit, oil, pad, Patch, pattern, people, pharmaceutical, Pharmascience, physician, practice, purpose, reach, real, Reconciliation, rejection, relationship, reorganization, resorbable, rest, restructuring, resuming, Saudi, scale, stem, streamlining, strict, submission, Subsequent, substance, substantial, substantially, tailored, Treme, Turkey, unchanged, upheld, version, workforce

Removed: accounted, Acting, Advisory, affiliated, alternative, application, aseptic, Commencing, committed, consecutive, consistency, crowded, delivered, denied, depreciation, determine, escalation, expensed, expired, forward, GAAP, government, greater, informing, June, Korean, MA, manufacturer, mechanism, meeting, modified, offering, open, Panel, performing, prescribed, presented, pressure, prioritize, put, qualitative, reduced, refusing, request, scientific, simplify, single, slightly, step, strength, structure, testing, Union, unoccupied, volume, Woburn, worldwide

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ANIK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Section 906 Certification

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2013	/s/ CHARLES H. SHERWOOD
	Charles H. Sherwood, Ph.D.
	Chief Executive Officer
	Principal Executive Officer

Date: May 6, 2013	/s/ SYLVIA CHEUNG
	Sylvia Cheung
	Chief Financial Officer
	Principal Financial Officer

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Exchange Act.